Compare PLAY & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAY | KMDA |
|---|---|---|
| Founded | 1982 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 460.3M |
| IPO Year | 2011 | 2013 |
| Metric | PLAY | KMDA |
|---|---|---|
| Price | $9.90 | $7.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $23.83 | $14.00 |
| AVG Volume (30 Days) | ★ 1.5M | 29.6K |
| Earning Date | 06-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.57 | $13.94 |
| Revenue Next Year | $5.00 | $9.84 |
| P/E Ratio | $60.94 | ★ $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $6.50 |
| 52 Week High | $33.30 | $9.35 |
| Indicator | PLAY | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 44.11 |
| Support Level | $9.50 | $6.97 |
| Resistance Level | $10.85 | $7.25 |
| Average True Range (ATR) | 0.68 | 0.13 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 33.10 | 32.14 |
Dave & Buster's Entertainment Inc is an owner and operator of entertainment and dining venues in North America that offer experiences for both adults and families under the Dave & Buster's and Main Event brands. The company combines various forms of entertainment, including games, bowling, and watching live sports and other televised events, with a full menu of entrees and appetizers and a selection of alcoholic and non alcoholic beverages, all in one location. Its concept focuses on providing customers the opportunity to Eat, Drink, Play, and Watch, appealing to a balanced mix of adults, families, and teenagers. The company also operates internationally in the early stage as a franchisor of the Dave & Buster's brand.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.